On July 27, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") first self-developed product "atomoxetine hydrochloride oral solution (trade name: 贝择思®)” has been successfully approved by the Chinese CDE for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older, and Beimei Pharmaceutical is the MAH of this product.

Atomoxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the first non-stimulant drug used for the treatment of children and adults with ADHD and is recommended by the latest guidelines for ADHD in China. Compared with central nervous system stimulants such as methylphenidate (a controlled drug), it has a lower risk of addiction and is more convenient to prescribe.

Atomoxetine hydrochloride oral solution (trade name: 贝择思®) is an oral solution with a dosing device, which can provide accurate dosage for children patients. Compared with the original capsule dosage form, it is more suitable for children to take, which improves medication safety and compliance, and the sweet taste of raspberry fruit also increases the children's medication compliance. The approval of atomoxetine hydrochloride oral solution (trade name: 贝择思®) will bring new options for more ADHD patients and their families.

Atomoxetine hydrochloride oral solution (trade name: 贝择思®) is the first approved product of Beimei Pharmaceutical and the first approved central nervous system (CNS) drug of the company. Beimei Pharmaceutical’s CNS pipeline of epilepsy, schizophrenia, depression and other products, will keep being applied and approved, continue to provide more treatment options for children.

About Shenzhen Beimei Pharmaceutical Co., Ltd.

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated. 

For more information, please visit our website at http://www.beimeiyaoye.com